ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for £150,000 in total. The new shares represent 0.9% of the company’s enlarged share capital.

Current stock price: 6.36 pence

12-month change: down 19%

Copyright 2022 Alliance News Limited. All Rights Reserved.